Business Daily BBC Podcasts

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of Mounjaro. But with competitors desperate for a piece of the action, how long can these two giants stay in front?
Leanna Byrne hears from some of the companies involved, including those at the centre of the action and those developing the next wave of treatments.
Presented by Leanna Byrne and produced by Lexy O'Connor
(Image: A box of the anti-obesity drug Wegovy, including injection pens. Credit: Getty Images)

In the first of a two-part series, in collaboration with The Food Chain, we look at the impact of the success of weight-loss drug manufacturer Novo Nordisk on the small country of Denmark.
The Scandinavian nation is where the company is based, and with a population of less than six million people, Novo is having an outsized impact on the economy there. Denmark is now publishing separate economic statistics, minus the pharmaceutical industry.
One town in particular, Kalundborg, has seen huge change since the company set up its manufacturing facility there. We look at the impact on local business; hearing from the town's residents, who now have quite different economic prospects.
Presented/producer: Adrienne Murray
(Photo: The headquarters of Novo Nordisk in Denmark, viewed from above. Credit: Getty Images)

President Biden has claimed the US economy is the ‘envy of the world’ and that his administration has added record job numbers, with around one million people hired since the turn of this year.
With inflation falling and the possibility of the Federal Reserve cutting interest rates, we find out if the rosy economic picture is being felt by those who are hiring or trying to get hired.
(Image: A sign on a wall recruiting for staff at a hotel in California in 2024 as a man walks by. Credit: Getty Images)
Presented and produced by Matt Lines